Ptc Therapeutics (PTCT) Equity Ratio (2012 - 2026)

Ptc Therapeutics' Equity Ratio history runs 15 years deep, the most recent figure standing at 0.06 for Q1 2026.

• In Q1 2026, Equity Ratio rose 10.09% year-over-year to 0.06; the TTM figure through Mar 2026 stood at 0.06 (up 10.09% YoY), while the FY2025 annual figure was 0.07, up 89.0% from the prior year.
• Equity Ratio was 0.06 for Q1 2026 at Ptc Therapeutics, up from 0.07 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.05 in Q1 2022 to a low of 0.64 in Q4 2024.
• Historically, Equity Ratio has averaged 0.28 across 5 years, with a median of 0.2 in 2022.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio slumped 27526.0% in 2022, then jumped 89.71% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.2 in 2022, then sank by 112.19% to 0.43 in 2023, then sank by 49.15% to 0.64 in 2024, then jumped by 89.0% to 0.07 in 2025, then advanced by 11.19% to 0.06 in 2026.
• The last three Equity Ratio figures came in at 0.06 (Q1 2026), 0.07 (Q4 2025), and 0.06 (Q3 2025), per Business Quant data.